Compare
Atossa Therapeutics, Inc. vs Akari Therapeutics Plc vs Verrica Pharmaceuticals Inc. vs Vistagen Therapeutics, Inc.
| Latest fiscal year | Atossa Therapeutics, Inc. ATOS | Akari Therapeutics Plc AKTX | Verrica Pharmaceuticals Inc. VRCA | Vistagen Therapeutics, Inc. VTGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | n/a | n/a | $35.58M | $1.27M |
| Revenue growth (YoY) | n/a | n/a | +370.2% | +161.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -34.2% | n/m |
| Net margin | n/a | n/a | -50.3% | n/m |
| Net income | -$34.77M | -$17.30M | -$17.89M | -$69.69M |
| EPS (Diluted) | -$4.04 | $0.00 | -$1.68 | -$1.83 |
| Operating cash flow | -$29.76M | -$10.57M | -$17.63M | -$66.44M |
| Free cash flow | -$29.79M | n/a | -$17.63M | n/a |
| Cash & equivalents | $41.30M | $0 | $30.15M | $30.79M |
| Total assets | $47.61M | $47.89M | $47.13M | $48.56M |
| Total liabilities | $8.26M | $19.56M | $22.39M | $13.04M |
| Shareholders' equity | $39.35M | $28.33M | $24.74M | $35.52M |
| Return on year-end equity | -88.4% | -61.1% | -72.3% | -196.2% |
| Shares outstanding | 8.61M | 90.54B | 17.18M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Atossa Therapeutics, Inc. | Akari Therapeutics Plc | Verrica Pharmaceuticals Inc. | Vistagen Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.8K Ended 2015-12-31 | n/a | $35.58M Ended 2025-12-31 | $1.27M Ended 2026-03-31 |
| 1 year earlier | $40.1K Ended 2014-12-31 | n/a | $7.57M Ended 2024-12-31 | $486.0K Ended 2025-03-31 |
| 2 years earlier | $632.6K Ended 2013-12-31 | n/a | $5.12M Ended 2023-12-31 | $1.06M Ended 2024-03-31 |
| 3 years earlier | $481.8K Ended 2012-12-31 | n/a | $9.03M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.5K Ended 2011-12-31 | n/a | $12.00M Ended 2021-12-31 | $1.11M Ended 2022-03-31 |